Ewa Kalinka-Warzocha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ewa Kalinka-Warzocha has a total of 802 co-authors. Here are the top co-authors by number of shared publications:
- Paweł Krawczyk
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland
14 shared publications - Krzysztof Warzocha
Klinika Hematologii, Instytut Hematologii i Transfuzjologii, ul. Indiry Gandhi 14, 02–776 Warszawa, Polska
11 shared publications - Kamila Wojas-Krawczyk
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland
10 shared publications Janusz Milanowski
Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland
9 shared publications- Ewa Lech-Maranda
Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland
8 shared publications - Rodryg Ramlau
Department of Oncology, Poznań University of Medical Sciences, Poznań, Poland, Poland
8 shared publications
Latest Publications
- Open Access
Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab
Background: With an ongoing debate concerning the optimal timing of advanced ovarian cancer surgical treatment, primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (IDS), this study aimed to compare survival outcomes between PDS and IDS populations and evaluate prognostic factors in a real-world cohort of patients treated with first-line chemotherapy and bevacizumab. Methods: A retrospective multi-center study was conducted involving 369 patients with newly diagnosed advanced ovarian cancer. Patient data included demographics, histology, treatment details, chemotherapy response, and survival outcomes. Kaplan–Meier estimates with log-rank tests were used for univariate analyses, as well as Cox proportional hazard models for multivariate analyses. Results: Patients undergoing IDS were older (62.5 vs. 60.0 years), had higher pretreatment CA-125 (1846 vs. 395.6 IU/mL), an increased proportion were at with stage IV (36.25% vs. 21.10%), and they received fewer bevacizumab cycles (12 vs. 18) compared to those undergoing PDS. Median progression-free survival (PFS) was 18.6 months (95% CI: 17.3–20.2) and overall survival (OS) was 45.4 months (95% CI: 41.1–52.1). Multivariate analysis confirmed poor chemotherapy response (HR 1.80, 95% CI: 1.36–2.37; p < 0.0001) and IDS (HR 1.65, 95% CI: 1.37–2.39; p < 0.0001) as independent predictors of shorter PFS. For OS, independent risk factors were age > 70 (HR 1.62; p = 0.0202), poor response (HR 2.03; p < 0.0001), and IDS (HR 1.75; p = 0.0006). Conclusions: In this real-world cohort treated with first-line chemotherapy and bevacizumab, interval debulking surgery was associated with inferior progression-free and overall survival compared with primary debulking surgery. However, these findings reflect a high-risk population and are strongly influenced by patient selection and treatment pathways, underscoring the need for cautious interpretation.
Open AccessReal-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab
Background: With an ongoing debate concerning the optimal timing of advanced ovarian cancer surgical treatment, primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (IDS), this study aimed to compare survival outcomes between PDS and IDS populations and evaluate prognostic factors in a real-world cohort of patients treated with first-line chemotherapy and bevacizumab. Methods: A retrospective multi-center study was conducted involving 369 patients with newly diagnosed advanced ovarian cancer. Patient data included demographics, histology, treatment details, chemotherapy response, and survival outcomes. Kaplan–Meier estimates with log-rank tests were used for univariate analyses, as well as Cox proportional hazard models for multivariate analyses. Results: Patients undergoing IDS were older (62.5 vs. 60.0 years), had higher pretreatment CA-125 (1846 vs. 395.6 IU/mL), an increased proportion were at with stage IV (36.25% vs. 21.10%), and they received fewer bevacizumab cycles (12 vs. 18) compared to those undergoing PDS. Median progression-free survival (PFS) was 18.6 months (95% CI: 17.3–20.2) and overall survival (OS) was 45.4 months (95% CI: 41.1–52.1). Multivariate analysis confirmed poor chemotherapy response (HR 1.80, 95% CI: 1.36–2.37; p < 0.0001) and IDS (HR 1.65, 95% CI: 1.37–2.39; p < 0.0001) as independent predictors of shorter PFS. For OS, independent risk factors were age > 70 (HR 1.62; p = 0.0202), poor response (HR 2.03; p < 0.0001), and IDS (HR 1.75; p = 0.0006). Conclusions: In this real-world cohort treated with first-line chemotherapy and bevacizumab, interval debulking surgery was associated with inferior progression-free and overall survival compared with primary debulking surgery. However, these findings reflect a high-risk population and are strongly influenced by patient selection and treatment pathways, underscoring the need for cautious interpretation.
- Open Access
- 22 December 2025
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (4) , 100947
First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials
- 22 December 2025
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (4) , 100947
Open AccessFirst-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials
- Open Access
- 1 December 2025
- Published by Taylor & Francis in ImmunoTargets and Therapy
- Vol. ume 14, 1455-1478
Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review
The introduction of immune checkpoint inhibitors (ICIs) in the treatment of cancer has significantly improved patient outcomes. Whereas ICIs have a substantially more beneficial risk profile than chemotherapy, immune-related adverse events (irAEs) are currently among the most pressing challenges of clinical oncology. It has been well established that certain variants of HLA genes are associated with increased susceptibility or a decreased risk of certain autoimmune diseases. Considering that irAEs often resemble autoimmune disorders observed in the general population, we conducted the first review summarizing the current knowledge on the link between the HLA system and the development of irAEs during ICIs treatment. We performed a comprehensive search of the US National Library of Medicine (PubMed) database. Based on the research conducted so far, our analysis indicates that certain HLA variants have been described to increase or, conversely, decrease the risk of irAEs. Thus, HLA genotyping may be useful in stratifying the risk of irAEs, allowing for more thorough screening of patients with a higher likelihood of developing ICI-related toxicities and less frequent monitoring of those at lower risk, thereby significantly reducing costs and the overall burden of disease. HLA genotyping may ultimately contribute to the personalization of cancer therapy, significantly improving patient safety and clinical efficacy. Furthermore, identifying an association between certain HLA variants and irAEs may lead to a better understanding of the pathogenesis underlying these adverse effects. Nevertheless, the studies conducted so far have included limited cohorts of patients with a wide variety of malignancies and diverse treatment regimens. Hence, further research that addresses these limitations is needed.
- 1 December 2025
- Published by Taylor & Francis in ImmunoTargets and Therapy
- Vol. ume 14, 1455-1478
Open AccessImmune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review
The introduction of immune checkpoint inhibitors (ICIs) in the treatment of cancer has significantly improved patient outcomes. Whereas ICIs have a substantially more beneficial risk profile than chemotherapy, immune-related adverse events (irAEs) are currently among the most pressing challenges of clinical oncology. It has been well established that certain variants of HLA genes are associated with increased susceptibility or a decreased risk of certain autoimmune diseases. Considering that irAEs often resemble autoimmune disorders observed in the general population, we conducted the first review summarizing the current knowledge on the link between the HLA system and the development of irAEs during ICIs treatment. We performed a comprehensive search of the US National Library of Medicine (PubMed) database. Based on the research conducted so far, our analysis indicates that certain HLA variants have been described to increase or, conversely, decrease the risk of irAEs. Thus, HLA genotyping may be useful in stratifying the risk of irAEs, allowing for more thorough screening of patients with a higher likelihood of developing ICI-related toxicities and less frequent monitoring of those at lower risk, thereby significantly reducing costs and the overall burden of disease. HLA genotyping may ultimately contribute to the personalization of cancer therapy, significantly improving patient safety and clinical efficacy. Furthermore, identifying an association between certain HLA variants and irAEs may lead to a better understanding of the pathogenesis underlying these adverse effects. Nevertheless, the studies conducted so far have included limited cohorts of patients with a wide variety of malignancies and diverse treatment regimens. Hence, further research that addresses these limitations is needed.
- Open Access
Evaluating the Utility of Fresh Tissue in Molecular Diagnostics of Colorectal Cancer
Background: Molecular diagnostics has become a critical component of precision oncology in solid tumors, including colorectal cancer, yet the use of formalin-fixed, paraffin-embedded (FFPE) tissue often suffers from DNA degradation that compromises sequencing quality. This study aimed to evaluate the feasibility and effectiveness of using fresh, intraoperatively collected tumor tissue for next-generation sequencing-based molecular diagnostics in colorectal cancer. Methods: Tissue samples from 24 patients undergoing colorectal tumor resection were obtained based on macroscopic evaluation and tested with a custom gene panel. Sequencing metrics, mutation profiles, and correlations with clinical and pathological features were analyzed. Results: All samples yielded high-quality sequencing data. Oncogenic or likely oncogenic variants were detected in 21 out of 24 samples (87.5%), predominantly affecting genes frequently involved in colorectal cancer carcinogenesis, including APC, TP53, and KRAS. In three cases, no typical mutations were found despite visual confirmation of tumor tissue during surgery, which may be attributed to insufficient tumor cellularity or molecular alterations beyond the panel’s scope. Conclusions: The results support the use of fresh tissue as a high-quality source for molecular diagnostics, capable of reducing turnaround time and avoiding formalin-induced artifacts. However, the findings also highlight the diagnostic risk of relying solely on macroscopic tumor assessment without histological confirmation. Overall, fresh tissue-based testing represents a promising yet currently investigational approach that can enhance molecular diagnostics in colorectal cancer.
Open AccessEvaluating the Utility of Fresh Tissue in Molecular Diagnostics of Colorectal Cancer
Background: Molecular diagnostics has become a critical component of precision oncology in solid tumors, including colorectal cancer, yet the use of formalin-fixed, paraffin-embedded (FFPE) tissue often suffers from DNA degradation that compromises sequencing quality. This study aimed to evaluate the feasibility and effectiveness of using fresh, intraoperatively collected tumor tissue for next-generation sequencing-based molecular diagnostics in colorectal cancer. Methods: Tissue samples from 24 patients undergoing colorectal tumor resection were obtained based on macroscopic evaluation and tested with a custom gene panel. Sequencing metrics, mutation profiles, and correlations with clinical and pathological features were analyzed. Results: All samples yielded high-quality sequencing data. Oncogenic or likely oncogenic variants were detected in 21 out of 24 samples (87.5%), predominantly affecting genes frequently involved in colorectal cancer carcinogenesis, including APC, TP53, and KRAS. In three cases, no typical mutations were found despite visual confirmation of tumor tissue during surgery, which may be attributed to insufficient tumor cellularity or molecular alterations beyond the panel’s scope. Conclusions: The results support the use of fresh tissue as a high-quality source for molecular diagnostics, capable of reducing turnaround time and avoiding formalin-induced artifacts. However, the findings also highlight the diagnostic risk of relying solely on macroscopic tumor assessment without histological confirmation. Overall, fresh tissue-based testing represents a promising yet currently investigational approach that can enhance molecular diagnostics in colorectal cancer.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study
PURPOSE: Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may overcome PD-1/PD-L1 inhibitor primary resistance. This phase II study investigated efti plus pembrolizumab treatment in patients with first-line metastatic non–small cell lung cancer (NSCLC) unselected for PD-L1. METHODS: Patients, naïve to systemic therapy in the metastatic setting, received efti (30 mg subcutaneously every 2 weeks for eight 3-week cycles, then every 3 weeks up to 54 weeks) plus pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks). The primary end point was objective response rate (ORR) by immune RECIST. Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and tolerability. Exploratory end points included identification and characterization of biomarkers. PD-L1 tumor proportion score (TPS) was assessed centrally. RESULTS: In the intention-to-treat population (n = 114), the median age was 67 years (range, 44-85), 73.7% was male, and 62.3% had an Eastern Cooperative Oncology Group performance status score of 1. Most patients (77.8%) had low/negative (<50%) PD-L1 TPS. The unconfirmed ORR (iRECIST) was 40.4%, leading to a confirmed ORR of 35.1%. The median DoR was 21.6 months, the DCR was 72.8%, and the median PFS (iRECIST) was 6.6 months. The median OS was 20.2 months, with 44.7% patients alive at 24 months. Antitumor activity was seen across all PD-L1 levels. A low proportion of patients had treatment-related adverse events leading to permanent discontinuation (8.8%). CONCLUSION: The APC activator, efti, on top of pembrolizumab was well tolerated and showed encouraging antitumor activity in patients with first-line NSCLC irrespective of tumor PD-L1 expression.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study
PURPOSE: Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may overcome PD-1/PD-L1 inhibitor primary resistance. This phase II study investigated efti plus pembrolizumab treatment in patients with first-line metastatic non–small cell lung cancer (NSCLC) unselected for PD-L1. METHODS: Patients, naïve to systemic therapy in the metastatic setting, received efti (30 mg subcutaneously every 2 weeks for eight 3-week cycles, then every 3 weeks up to 54 weeks) plus pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks). The primary end point was objective response rate (ORR) by immune RECIST. Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and tolerability. Exploratory end points included identification and characterization of biomarkers. PD-L1 tumor proportion score (TPS) was assessed centrally. RESULTS: In the intention-to-treat population (n = 114), the median age was 67 years (range, 44-85), 73.7% was male, and 62.3% had an Eastern Cooperative Oncology Group performance status score of 1. Most patients (77.8%) had low/negative (<50%) PD-L1 TPS. The unconfirmed ORR (iRECIST) was 40.4%, leading to a confirmed ORR of 35.1%. The median DoR was 21.6 months, the DCR was 72.8%, and the median PFS (iRECIST) was 6.6 months. The median OS was 20.2 months, with 44.7% patients alive at 24 months. Antitumor activity was seen across all PD-L1 levels. A low proportion of patients had treatment-related adverse events leading to permanent discontinuation (8.8%). CONCLUSION: The APC activator, efti, on top of pembrolizumab was well tolerated and showed encouraging antitumor activity in patients with first-line NSCLC irrespective of tumor PD-L1 expression.
- Open Access
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene
The advancement of genetic research has changed the treatment management of non-small cell lung cancer (NSCLC) and opened the era of personalized medicine. Currently, three generations of EGFR tyrosine kinase inhibitors (TKIs) are used in the treatment of NSCLC patients with activating mutations in the EGFR gene, and ongoing clinical trials examine the safety and effectiveness of new third and fourth generations. Osimertinib, a third generation of TKIs that binds irreversibly to abnormal tyrosine kinase, may be applied in various indications in patients with NSCLC: (i) in the second and subsequent lines of therapy in patients with resistance to first-generation or second-generation EGFR TKIs, (ii) in the first line of treatment in monotherapy in NSCLC patients with frequent or rare EGFR mutations, (iii) in combination with chemotherapy in patients with locally advanced or metastatic NSCLC with frequent EGFR mutations, (iv) in consolidation therapy in patients with locally advanced NSCLC who had previously received chemoradiotherapy, (v) in adjuvant treatment of NSCLC patients with stage IB—IIIA undergoing radical surgical resection. Despite the high efficacy of osimertinib in NSCLC patients harboring EGFR mutations, resistance driven in EGFR-dependent or EGFR-independent mechanisms may occur. Since resistance to osimertinib is poorly understood, the following review presents the overview of resistance mechanisms to osimertinib, methodological approaches for the resistance diagnosis, and the up-to-date treatment possibilities for overcoming the resistance process.
Open AccessPossibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene
The advancement of genetic research has changed the treatment management of non-small cell lung cancer (NSCLC) and opened the era of personalized medicine. Currently, three generations of EGFR tyrosine kinase inhibitors (TKIs) are used in the treatment of NSCLC patients with activating mutations in the EGFR gene, and ongoing clinical trials examine the safety and effectiveness of new third and fourth generations. Osimertinib, a third generation of TKIs that binds irreversibly to abnormal tyrosine kinase, may be applied in various indications in patients with NSCLC: (i) in the second and subsequent lines of therapy in patients with resistance to first-generation or second-generation EGFR TKIs, (ii) in the first line of treatment in monotherapy in NSCLC patients with frequent or rare EGFR mutations, (iii) in combination with chemotherapy in patients with locally advanced or metastatic NSCLC with frequent EGFR mutations, (iv) in consolidation therapy in patients with locally advanced NSCLC who had previously received chemoradiotherapy, (v) in adjuvant treatment of NSCLC patients with stage IB—IIIA undergoing radical surgical resection. Despite the high efficacy of osimertinib in NSCLC patients harboring EGFR mutations, resistance driven in EGFR-dependent or EGFR-independent mechanisms may occur. Since resistance to osimertinib is poorly understood, the following review presents the overview of resistance mechanisms to osimertinib, methodological approaches for the resistance diagnosis, and the up-to-date treatment possibilities for overcoming the resistance process.
- Open Access
- 7 September 2024
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 179, 175-181
Level of selected exponents of the kynurenine pathway in patients diagnosed with depression and selected cancers
- 7 September 2024
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 179, 175-181
Open AccessLevel of selected exponents of the kynurenine pathway in patients diagnosed with depression and selected cancers
- Open Access
NRG1 Gene Fusions—What Promise Remains Behind These Rare Genetic Alterations? A Comprehensive Review of Biology, Diagnostic Approaches, and Clinical Implications
Non-small cell lung cancer (NSCLC) presents a variety of druggable genetic alterations that revolutionized the treatment approaches. However, identifying new alterations may broaden the group of patients benefitting from such novel treatment options. Recently, the interest focused on the neuregulin-1 gene (NRG1), whose fusions may have become a potential predictive factor. To date, the occurrence of NRG1 fusions has been considered a negative prognostic marker in NSCLC treatment; however, many premises remain behind the targetability of signaling pathways affected by the NRG1 gene. The role of NRG1 fusions in ErbB-mediated cell proliferation especially seems to be considered as a main target of treatment. Hence, NSCLC patients harboring NRG1 fusions may benefit from targeted therapies such as pan-HER family inhibitors, which have shown efficacy in previous studies in various cancers, and anti-HER monoclonal antibodies. Considering the increased interest in the NRG1 gene as a potential clinical target, in the following review, we highlight its biology, as well as the potential clinical implications that were evaluated in clinics or remained under consideration in clinical trials.
Open AccessNRG1 Gene Fusions—What Promise Remains Behind These Rare Genetic Alterations? A Comprehensive Review of Biology, Diagnostic Approaches, and Clinical Implications
Non-small cell lung cancer (NSCLC) presents a variety of druggable genetic alterations that revolutionized the treatment approaches. However, identifying new alterations may broaden the group of patients benefitting from such novel treatment options. Recently, the interest focused on the neuregulin-1 gene (NRG1), whose fusions may have become a potential predictive factor. To date, the occurrence of NRG1 fusions has been considered a negative prognostic marker in NSCLC treatment; however, many premises remain behind the targetability of signaling pathways affected by the NRG1 gene. The role of NRG1 fusions in ErbB-mediated cell proliferation especially seems to be considered as a main target of treatment. Hence, NSCLC patients harboring NRG1 fusions may benefit from targeted therapies such as pan-HER family inhibitors, which have shown efficacy in previous studies in various cancers, and anti-HER monoclonal antibodies. Considering the increased interest in the NRG1 gene as a potential clinical target, in the following review, we highlight its biology, as well as the potential clinical implications that were evaluated in clinics or remained under consideration in clinical trials.
- Top Cited PapersOpen Access
- 28 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5893
Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection
Endometrial cancer (EC) accounts for 90% of uterine cancer cases. It is considered not only one of the most common gynecological malignancies but also one of the most frequent cancers among women overall. Nowadays, the differentiation of EC subtypes is based on immunohistochemistry and molecular techniques. It is considered that patients’ prognosis and the implementation of the appropriate treatment depend on the cancer subtype. Patients with pathogenic variants in POLE have the most favorable outcome, while those with abnormal p53 protein have the poorest. Therefore, in patients with POLE mutation, the de-escalation of postoperative treatment may be considered, and patients with abnormal p53 protein should be subjected to intensive adjuvant therapy. Patients with a DNA mismatch repair (dMMR) deficiency are classified in the intermediate prognosis group as EC patients without a specific molecular profile. Immunotherapy has been recognized as an effective treatment method in patients with advanced or recurrent EC with a mismatch deficiency. Thus, different adjuvant therapy approaches, including targeted therapy and immunotherapy, are being proposed depending on the EC subtype, and international guidelines, such as those published by ESMO and ESGO/ESTRO/ESP, include recommendations for performing the molecular classification of all EC cases. The decision about adjuvant therapy selection has to be based not only on clinical data and histological type and stage of cancer, but, following international recommendations, has to include EC molecular subtyping. This review describes how molecular classification could support more optimal therapeutic management in endometrial cancer patients.
- 28 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5893
Top Cited PapersOpen AccessMolecular Classification of Endometrial Cancer and Its Impact on Therapy Selection
Endometrial cancer (EC) accounts for 90% of uterine cancer cases. It is considered not only one of the most common gynecological malignancies but also one of the most frequent cancers among women overall. Nowadays, the differentiation of EC subtypes is based on immunohistochemistry and molecular techniques. It is considered that patients’ prognosis and the implementation of the appropriate treatment depend on the cancer subtype. Patients with pathogenic variants in POLE have the most favorable outcome, while those with abnormal p53 protein have the poorest. Therefore, in patients with POLE mutation, the de-escalation of postoperative treatment may be considered, and patients with abnormal p53 protein should be subjected to intensive adjuvant therapy. Patients with a DNA mismatch repair (dMMR) deficiency are classified in the intermediate prognosis group as EC patients without a specific molecular profile. Immunotherapy has been recognized as an effective treatment method in patients with advanced or recurrent EC with a mismatch deficiency. Thus, different adjuvant therapy approaches, including targeted therapy and immunotherapy, are being proposed depending on the EC subtype, and international guidelines, such as those published by ESMO and ESGO/ESTRO/ESP, include recommendations for performing the molecular classification of all EC cases. The decision about adjuvant therapy selection has to be based not only on clinical data and histological type and stage of cancer, but, following international recommendations, has to include EC molecular subtyping. This review describes how molecular classification could support more optimal therapeutic management in endometrial cancer patients.
- Open Access
- 13 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 193, 107821
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
- 13 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 193, 107821
Open AccessCemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial